McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will not resume selling the OTC products that were the subject of the recall until 2011.
You may also be interested in...
Rx Manufacturing Safety Bill Resurfaces Without Inspection Fees
FDA's foreign and domestic oversight powers would increase under the legislation, which has been stripped down in an apparent effort to speed passage.
Rx Manufacturing Safety Bill Resurfaces Without Inspection Fees
FDA's foreign and domestic oversight powers would increase under the legislation, which has been stripped down in an apparent effort to speed passage.
J&J Pharma Hit By EU Price Cuts, Weaker Euro
Hit from EU pricing cuts is estimated at about $200 million in 2010.